The RDCA-DAP Workshop Speakers Have Been Announced

The RDCA-DAP Workshop Speakers Have Been Announced

With less than one week left to register, we are ready to welcome rare disease stakeholders to Virginia for a 1.5-day workshop to demonstrate next-level platform demonstrations and case studies, industry expert presentations, panel discussions, and more.

Patients, providers, researchers, clinicians, biopharmaceutical companies, regulatory reviewers, patient advocacy groups, and scientists who attend will leave with an understanding of:

  • RDCA-DAP’s current and future impact on drug development in rare diseases from the perspectives of patients, regulators, and industry partners.
  • How RDCA-DAP is unique in supporting multiple data and analysis-types across rare diseases.
  • The critical importance of building a rare disease community that works together to share optimal data and generate actionable solutions for the benefit of all rare disease patients.


RDCA-DAP is an integrated database and analytics hub that is designed to be used in building novel tools to accelerate drug development across rare diseases. It has been developed by the Critical Path Institute (C-Path) and the National Organization for Rare Disorders (NORD) through a collaborative grant from the US Food and Drug Administration (FDA). Data for the platform is shared from various sources including clinical data from industry, research data from academics, patient registry data from NORD, and other patient registry sources willing to share. Types of accepted data will continue to expand as the platform develops.

RDCA-DAP helps drive research and understanding in rare diseases by combining data in a common database to enable researchers, medical professionals, and patients to uncover similarities and commonalities, which could lead to a better understanding of biomarkers and treatments.

C-Path and NORD offer two different perspectives for different audiences with a shared goal: accelerating the development of cures for patients.

This initiative is made possible through a collaborative grant from the FDA [Critical Path Public-Private Partnerships Grant Number U18 FD005320 from the US Food and Drug Administration].

To learn more, visit or email




NORD logo
NORD, a 501(c)(3) organization, is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them. NORD, along with its more than 330 patient organization members, is committed to the identification, treatment and cure of rare disorders through programs of education, advocacy, research and patient services.
Publicado en Convocatorias.

Cuba, La Habana. Investigador Titular del Centro de Investigaciones Pesqueras, doctor en Ciencias en el Uso, Manejo y Preservación de los Recursos, y maestro en Ciencias del Agua.

Deja una respuesta

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *